JP6436402B6 - 感知フォーリー・カテーテル - Google Patents
感知フォーリー・カテーテル Download PDFInfo
- Publication number
- JP6436402B6 JP6436402B6 JP2016524238A JP2016524238A JP6436402B6 JP 6436402 B6 JP6436402 B6 JP 6436402B6 JP 2016524238 A JP2016524238 A JP 2016524238A JP 2016524238 A JP2016524238 A JP 2016524238A JP 6436402 B6 JP6436402 B6 JP 6436402B6
- Authority
- JP
- Japan
- Prior art keywords
- pressure
- catheter
- balloon
- assembly
- sensing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000012530 fluid Substances 0.000 claims description 157
- 238000000034 method Methods 0.000 claims description 102
- 230000007246 mechanism Effects 0.000 claims description 51
- 238000004891 communication Methods 0.000 claims description 41
- 230000000747 cardiac effect Effects 0.000 claims description 40
- 239000012491 analyte Substances 0.000 claims description 37
- 230000014759 maintenance of location Effects 0.000 claims description 33
- 230000036387 respiratory rate Effects 0.000 claims description 32
- 230000000694 effects Effects 0.000 claims description 27
- 239000007789 gas Substances 0.000 claims description 24
- 230000008569 process Effects 0.000 claims description 23
- 239000000835 fiber Substances 0.000 claims description 22
- 230000008859 change Effects 0.000 claims description 11
- 241000894006 Bacteria Species 0.000 claims description 9
- 210000004072 lung Anatomy 0.000 claims description 8
- 230000004044 response Effects 0.000 claims description 6
- 239000002207 metabolite Substances 0.000 claims description 5
- 239000003792 electrolyte Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 description 135
- 210000003932 urinary bladder Anatomy 0.000 description 123
- 239000003570 air Substances 0.000 description 79
- 238000005516 engineering process Methods 0.000 description 73
- 238000012545 processing Methods 0.000 description 53
- 239000012528 membrane Substances 0.000 description 38
- 210000004379 membrane Anatomy 0.000 description 35
- 230000033001 locomotion Effects 0.000 description 32
- 238000012544 monitoring process Methods 0.000 description 31
- 238000005259 measurement Methods 0.000 description 29
- 230000000638 stimulation Effects 0.000 description 22
- 210000001635 urinary tract Anatomy 0.000 description 22
- 238000009530 blood pressure measurement Methods 0.000 description 21
- 238000001802 infusion Methods 0.000 description 21
- 238000003032 molecular docking Methods 0.000 description 21
- 238000004140 cleaning Methods 0.000 description 20
- 238000010586 diagram Methods 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 238000001514 detection method Methods 0.000 description 17
- 239000007788 liquid Substances 0.000 description 17
- 230000037452 priming Effects 0.000 description 17
- 230000002485 urinary effect Effects 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 16
- 230000001965 increasing effect Effects 0.000 description 15
- 230000010412 perfusion Effects 0.000 description 15
- 230000002572 peristaltic effect Effects 0.000 description 15
- 230000000241 respiratory effect Effects 0.000 description 15
- 230000006870 function Effects 0.000 description 14
- 230000029058 respiratory gaseous exchange Effects 0.000 description 13
- 210000003708 urethra Anatomy 0.000 description 13
- 208000015181 infectious disease Diseases 0.000 description 12
- 230000003287 optical effect Effects 0.000 description 12
- 238000005096 rolling process Methods 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- 230000035945 sensitivity Effects 0.000 description 11
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 10
- 230000005540 biological transmission Effects 0.000 description 10
- 208000014674 injury Diseases 0.000 description 10
- 238000002106 pulse oximetry Methods 0.000 description 10
- 208000007536 Thrombosis Diseases 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 230000009471 action Effects 0.000 description 8
- 230000036772 blood pressure Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000006835 compression Effects 0.000 description 8
- 238000007906 compression Methods 0.000 description 8
- 239000007943 implant Substances 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 8
- 238000005086 pumping Methods 0.000 description 8
- 238000005070 sampling Methods 0.000 description 8
- 230000008733 trauma Effects 0.000 description 8
- 238000013459 approach Methods 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 230000002209 hydrophobic effect Effects 0.000 description 7
- 108010000849 leukocyte esterase Proteins 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 206010011224 Cough Diseases 0.000 description 6
- 210000000683 abdominal cavity Anatomy 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 210000000038 chest Anatomy 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 238000007912 intraperitoneal administration Methods 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000000115 thoracic cavity Anatomy 0.000 description 6
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 108010054147 Hemoglobins Proteins 0.000 description 5
- 208000037656 Respiratory Sounds Diseases 0.000 description 5
- 230000003187 abdominal effect Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000004877 mucosa Anatomy 0.000 description 5
- 230000035479 physiological effects, processes and functions Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 206010035664 Pneumonia Diseases 0.000 description 4
- 206010044565 Tremor Diseases 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- 230000036757 core body temperature Effects 0.000 description 4
- 238000013480 data collection Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000007667 floating Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000013307 optical fiber Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- OBHRVMZSZIDDEK-UHFFFAOYSA-N urobilinogen Chemical compound CCC1=C(C)C(=O)NC1CC1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(CC3C(=C(CC)C(=O)N3)C)N2)CCC(O)=O)N1 OBHRVMZSZIDDEK-UHFFFAOYSA-N 0.000 description 4
- 206010058808 Abdominal compartment syndrome Diseases 0.000 description 3
- 206010048994 Bladder spasm Diseases 0.000 description 3
- 208000002623 Intra-Abdominal Hypertension Diseases 0.000 description 3
- 208000004210 Pressure Ulcer Diseases 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 206010046555 Urinary retention Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000000315 cryotherapy Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 208000003243 intestinal obstruction Diseases 0.000 description 3
- 238000002496 oximetry Methods 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 230000010349 pulsation Effects 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- 239000003507 refrigerant Substances 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000009423 ventilation Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 102000010445 Lactoferrin Human genes 0.000 description 2
- 108010063045 Lactoferrin Proteins 0.000 description 2
- 238000004497 NIR spectroscopy Methods 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 2
- 108010048233 Procalcitonin Proteins 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 206010047924 Wheezing Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000009529 body temperature measurement Methods 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 230000002920 convulsive effect Effects 0.000 description 2
- 239000012809 cooling fluid Substances 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 201000003146 cystitis Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940078795 lactoferrin Drugs 0.000 description 2
- 235000021242 lactoferrin Nutrition 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000001690 micro-dialysis Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- 238000001874 polarisation spectroscopy Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 201000002859 sleep apnea Diseases 0.000 description 2
- 230000004617 sleep duration Effects 0.000 description 2
- 230000003860 sleep quality Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 210000000626 ureter Anatomy 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 229920002799 BoPET Polymers 0.000 description 1
- 0 C*C([C@@]1*[O+])C1=NC Chemical compound C*C([C@@]1*[O+])C1=NC 0.000 description 1
- NBCCTSSZAIBGLU-UHFFFAOYSA-N CC(CCC[N]#C)=C Chemical compound CC(CCC[N]#C)=C NBCCTSSZAIBGLU-UHFFFAOYSA-N 0.000 description 1
- 208000006017 Cardiac Tamponade Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 241000271569 Rhea Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 210000005068 bladder tissue Anatomy 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000000746 body region Anatomy 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229920000295 expanded polytetrafluoroethylene Polymers 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000036724 intravesical pressure Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 1
- 229910001000 nickel titanium Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 210000003281 pleural cavity Anatomy 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000036391 respiratory frequency Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 230000008667 sleep stage Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000002474 sphenoid bone Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- -1 urine pH Chemical compound 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/03—Detecting, measuring or recording fluid pressure within the body other than blood pressure, e.g. cerebral pressure; Measuring pressure in body tissues or organs
- A61B5/036—Detecting, measuring or recording fluid pressure within the body other than blood pressure, e.g. cerebral pressure; Measuring pressure in body tissues or organs by means introduced into body tracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0082—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes
- A61B5/0084—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for introduction into the body, e.g. by catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14507—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/20—Measuring for diagnostic purposes; Identification of persons for measuring urological functions restricted to the evaluation of the urinary system
- A61B5/202—Assessing bladder functions, e.g. incontinence assessment
- A61B5/205—Determining bladder or urethral pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
- A61B5/6847—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
- A61B5/6852—Catheters
- A61B5/6853—Catheters with a balloon
Description
本出願は、2013年6月27日出願の米国特許仮出願第61/840,408号、2013年10月21日出願の米国特許仮出願第61/893,816号、及び2013年8月16日出願の米国特許仮出願第61/959,144号に対する優先権の利益を主張するものであり、各出願の全体を参照により本明細書に組み込む。本出願は、2012年3月7日出願のPCT/US12/028071にも関連し、この出願を全体を参照により本明細書に組み込む。
Claims (21)
- 流体圧力感知組立体において、
長さ部及び拡張可能保持部材を有するカテーテルであって、前記拡張可能保持部材は、前記カテーテルの遠位端付近又は前記遠位端に位置し、前記カテーテルは、少なくとも部分的に前記カテーテル長さ部を通る排出管腔を画定し、前記排出管腔の遠位端が前記カテーテルの前記遠位端付近又は前記遠位端に画定した排出開口で終端するようにする、カテーテル;
排出管、及び前記排出管が前記排出開口と流体連通するように前記排出管腔に流体結合する貯蔵器であって、流体が、前記排出管腔を通して、前記排出開口に受け入れられる、
貯蔵器;
前記カテーテルの前記遠位端付近又は前記遠位端に位置する圧力感知機構であって、前記圧力感知機構が、前記圧力感知機構に加わる圧力の変化に応答して信号を生成する、圧力感知機構;並びに
前記排出管と連通する通気機構;
前記排出管を通る流体の流れが妨げられないように、前記排出管内で流体に周期的に及ぼされる負圧を形成するように連通されたポンプと、を備える流体圧力感知組立体。 - 前記カテーテルは、フォーリー型カテーテルを含む、請求項1に記載の組立体。
- 前記カテーテルの近位端に取り付けるように構成した適合器を更に備える、請求項1に記載の組立体であって、ポートは、前記適合器に流体結合する、組立体。
- 前記ポートは、前記排出管腔の長さ部に沿って前記排出管腔に流体結合するように構成される、請求項3に記載の組立体。
- 前記ポートは、前記排出管腔の近位端に流体結合するように構成される、請求項3に記載の組立体。
- 前記排出管は、患者の体外に位置するように構成される、請求項1に記載の組立体。
- 前記圧力感知機構は、圧力ラインを介して取り付けた圧力センサを更に備える、請求項1に記載の組立体。
- 前記圧力センサは、機械的圧力センサ又は光ファイバ圧力センサを備える、請求項7に記載の組立体。
- 前記圧力感知機構は、圧力感知バルーンを備える、請求項1に記載の組立体。
- 前記圧力感知機構は、前記圧力感知機構に当たった圧力を時系列圧力プロファイルに変換するように構成され、前記圧力プロファイルは、1つ又は複数の異なる生理学的圧力プロファイルに処理するのに十分な分解能を有し、前記生理学的圧力プロファイルは、呼吸数及び心拍数からなる群から選択される、請求項1に記載の組立体。
- 前記圧力プロファイルは、少なくとも約1Hzの周波数で変換器によってサンプリングしたとき、肺の相対1回換気量プロファイルをもたらすために、前記圧力プロファイルを処理できるような十分な分解能を有する、請求項10に記載の組立体。
- 前記圧力プロファイルは、少なくとも約5Hzの周波数で変換器によってサンプリングしたとき、心拍出量、相対心拍出量及び絶対心拍出量からなる群から選択される生理学的圧力プロファイルをもたらすために、前記圧力プロファイルを処理できるような十分な分解能を有する、請求項10に記載の組立体。
- 分析物センサを更に備える、請求項1に記載の組立体。
- 前記分析物センサは、pH、気体、電解質、代謝基質、代謝物、酵素及びホルモンからなる群から選択される分析物を感知するように構成される、請求項13に記載の組立体。
- 1つ又は複数の電気活動センサを更に備える、請求項1に記載の組立体。
- 光源及び光センサを更に備える、請求項1に記載の組立体であって、前記センサは、前記光源から放出された光を捕捉するように構成される、組立体。
- 前記排出管の内径は、約0.25インチ以下である、請求項1に記載の組立体。
- 前記排出管の内径は、約0.125インチ以下である、請求項1に記載の組立体。
- 前記圧力感知機構によって感知した圧力変化に部分的に基づいて腹腔内圧を決定するように構成した制御装置を更に備える、請求項1に記載の組立体。
- 前記制御装置は、患者のデータを記憶するように構成される、請求項19に記載の組立体。
- 前記分析物センサは、細菌を感知するように構成される、請求項13に記載の組立体。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361840408P | 2013-06-27 | 2013-06-27 | |
US61/840,408 | 2013-06-27 | ||
US201361959144P | 2013-08-16 | 2013-08-16 | |
US61/959,144 | 2013-08-16 | ||
US201361893816P | 2013-10-21 | 2013-10-21 | |
US61/893,816 | 2013-10-21 | ||
PCT/US2014/044565 WO2014210453A2 (en) | 2013-06-27 | 2014-06-27 | Sensing foley catheter |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018206198A Division JP6761843B2 (ja) | 2013-06-27 | 2018-11-01 | 流体圧力感知組立体 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016531650A JP2016531650A (ja) | 2016-10-13 |
JP6436402B2 JP6436402B2 (ja) | 2018-12-12 |
JP6436402B6 true JP6436402B6 (ja) | 2019-01-30 |
Family
ID=52142845
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016524238A Active JP6436402B6 (ja) | 2013-06-27 | 2014-06-27 | 感知フォーリー・カテーテル |
JP2018206198A Active JP6761843B2 (ja) | 2013-06-27 | 2018-11-01 | 流体圧力感知組立体 |
JP2020149786A Active JP7187510B2 (ja) | 2013-06-27 | 2020-09-07 | 感知フォーリー・カテーテル |
JP2022190883A Pending JP2023029920A (ja) | 2013-06-27 | 2022-11-30 | 感知フォーリー・カテーテル |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018206198A Active JP6761843B2 (ja) | 2013-06-27 | 2018-11-01 | 流体圧力感知組立体 |
JP2020149786A Active JP7187510B2 (ja) | 2013-06-27 | 2020-09-07 | 感知フォーリー・カテーテル |
JP2022190883A Pending JP2023029920A (ja) | 2013-06-27 | 2022-11-30 | 感知フォーリー・カテーテル |
Country Status (6)
Country | Link |
---|---|
US (1) | US20160183819A1 (ja) |
EP (2) | EP3884859A1 (ja) |
JP (4) | JP6436402B6 (ja) |
AU (4) | AU2014302183A1 (ja) |
CA (1) | CA2916939C (ja) |
WO (1) | WO2014210453A2 (ja) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8202248B2 (en) | 2004-08-18 | 2012-06-19 | Sequana Medical Ag | Dialysis implant and methods of use |
US9622670B2 (en) | 2010-07-09 | 2017-04-18 | Potrero Medical, Inc. | Method and apparatus for pressure measurement |
US9962516B2 (en) | 2010-09-09 | 2018-05-08 | University Of Florida Research Foundation, Incorporated | Context-sensitive flow interrupter and drainage outflow optimization system |
US9655555B2 (en) * | 2011-03-07 | 2017-05-23 | Potrero Medical, Inc. | Sensing foley catheter |
US8585635B2 (en) | 2012-02-15 | 2013-11-19 | Sequana Medical Ag | Systems and methods for treating chronic liver failure based on peritoneal dialysis |
WO2015105916A1 (en) | 2014-01-07 | 2015-07-16 | Consano, Inc. | Systems, devices and methods for draining and analyzing bodily fluids |
EP4233696A3 (en) | 2014-09-28 | 2023-09-06 | Potrero Medical, Inc. | Systems, devices and methods for sensing physiologic data and draining and analyzing bodily fluids |
US11040172B2 (en) | 2015-07-20 | 2021-06-22 | Strataca Systems Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
EP3636311B1 (en) * | 2015-07-20 | 2023-11-29 | Roivios Limited | Ureteral and bladder catheters for inducing negative pressure to increase renal perfusion |
US10926062B2 (en) | 2015-07-20 | 2021-02-23 | Strataca Systems Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
US10391275B2 (en) | 2015-11-17 | 2019-08-27 | Potrero Medical, Inc. | Systems, devices and methods for draining and analyzing bodily fluids |
US20190046101A1 (en) * | 2016-03-02 | 2019-02-14 | Tsukada Medical Research Co., Ltd. | Bladder urodynamic measurement apparatus |
SE540068C2 (en) * | 2016-06-07 | 2018-03-13 | Haurir Medical Ab | Body drainage apparatus with rotatable peristaltic pump |
WO2017213237A1 (ja) * | 2016-06-10 | 2017-12-14 | テルモ株式会社 | 酸素測定デバイス |
WO2018037360A1 (en) | 2016-08-26 | 2018-03-01 | Sequana Medical Ag | Systems and methods for managing and analyzing data generated by an implantable device |
US10716922B2 (en) | 2016-08-26 | 2020-07-21 | Sequana Medical Nv | Implantable fluid management system having clog resistant catheters, and methods of using same |
JP2018061836A (ja) * | 2016-10-07 | 2018-04-19 | 株式会社根本杏林堂 | 造影剤注入システム |
US10485483B1 (en) * | 2016-10-17 | 2019-11-26 | Srs Medical Systems, Llc | Diagnostic drainage catheter assembly and methods |
US10631788B2 (en) | 2016-10-17 | 2020-04-28 | Srs Medical Systems, Llc | Diagnostic drainage catheter assembly and methods |
US11065418B1 (en) * | 2016-10-17 | 2021-07-20 | Srs Medical Systems, Llc | Bladder storage anomaly assessment |
EP3372158B1 (de) * | 2017-03-08 | 2021-05-12 | Inomed Medizintechnik GmbH | System zur intraoperativen überwachung der funktionsfähigkeit von nerven |
WO2018180229A1 (ja) * | 2017-03-30 | 2018-10-04 | テルモ株式会社 | 酸素測定デバイス及び酸素測定システム |
KR101786981B1 (ko) * | 2017-04-25 | 2017-10-18 | 한국과학기술원 | 카테터 가이드 초소형 무선 체내 장기 컴플라이언스 센서 시스템 |
EP3612246B1 (en) | 2017-05-24 | 2020-12-30 | Sequana Medical NV | Direct sodium removal method, solution and apparatus to reduce fluid overload in heart failure patients |
US11559618B2 (en) | 2017-05-24 | 2023-01-24 | Sequana Medical Nv | Formulations and methods for direct sodium removal in patients having severe renal dysfunction |
US10799131B2 (en) | 2017-06-03 | 2020-10-13 | Sentinel Medical Technologies, LLC | Catheter for monitoring intrauterine pressure to protect the fallopian tubes |
US11045128B2 (en) | 2017-06-03 | 2021-06-29 | Sentinel Medical Technologies, LLC | Catheter for monitoring intra-abdominal pressure |
US11185245B2 (en) | 2017-06-03 | 2021-11-30 | Sentinel Medical Technologies, Llc. | Catheter for monitoring pressure for muscle compartment syndrome |
US10813589B2 (en) * | 2017-06-03 | 2020-10-27 | Sentinel Medical Technologies, LLC | Catheter for monitoring uterine contraction pressure |
US11045143B2 (en) | 2017-06-03 | 2021-06-29 | Sentinel Medical Technologies, LLC | Catheter with connectable hub for monitoring pressure |
US11179516B2 (en) | 2017-06-22 | 2021-11-23 | Baxter International Inc. | Systems and methods for incorporating patient pressure into medical fluid delivery |
US11395616B2 (en) | 2017-09-07 | 2022-07-26 | WSA Medical Ventures, LLC | Catheter assemblies, oxygen-sensing assemblies, and related methods |
US11660032B2 (en) | 2017-09-07 | 2023-05-30 | SWSA Medical Ventures, LLC | Catheter assemblies, oxygen-sensing assemblies, and related methods |
US11389071B2 (en) * | 2018-04-24 | 2022-07-19 | Covidien Lp | Surgical device including system for sensing tissue properties and methods thereof |
EP3784322B1 (en) * | 2018-05-22 | 2023-11-22 | C. R. Bard, Inc. | Catheterization system and methods for use thereof |
WO2019246126A1 (en) | 2018-06-19 | 2019-12-26 | Potrero Medical, Inc. | Equipment adaptor assembly and equipment stand |
US11911160B2 (en) | 2018-08-10 | 2024-02-27 | C. R. Bard, Inc. | Automated urine output measurement systems and methods thereof |
WO2020099560A1 (en) * | 2018-11-16 | 2020-05-22 | Danmarks Tekniske Universitet | Electrochemical sensor system comprising molecularly imprinted polymer for early warning of urinary tract infections |
US11672457B2 (en) | 2018-11-24 | 2023-06-13 | Sentinel Medical Technologies, Llc. | Catheter for monitoring pressure |
US11779263B2 (en) | 2019-02-08 | 2023-10-10 | Sentinel Medical Technologies, Llc. | Catheter for monitoring intra-abdominal pressure for assessing preeclampsia |
US20200324037A1 (en) | 2019-04-15 | 2020-10-15 | Medtronic, Inc. | Medical device dislodgment detection |
WO2020256898A1 (en) | 2019-06-19 | 2020-12-24 | Boston Scientific Scimed, Inc. | Balloon surface photoacoustic pressure wave generation to disrupt vascular lesions |
US11717139B2 (en) | 2019-06-19 | 2023-08-08 | Bolt Medical, Inc. | Plasma creation via nonaqueous optical breakdown of laser pulse energy for breakup of vascular calcium |
US11660427B2 (en) | 2019-06-24 | 2023-05-30 | Boston Scientific Scimed, Inc. | Superheating system for inertial impulse generation to disrupt vascular lesions |
US20200406010A1 (en) | 2019-06-26 | 2020-12-31 | Boston Scientific Scimed, Inc. | Side light direction plasma system to disrupt vascular lesions |
EP4009860A4 (en) | 2019-08-08 | 2022-11-16 | Sentinel Medical Technologies, LLC | CABLE FOR USE WITH PRESSURE MONITORING CATHETER |
CN110638482B (zh) * | 2019-10-18 | 2022-10-21 | 北京大学第三医院(北京大学第三临床医学院) | 一种肠鸣音和腹腔压力的实时监护系统 |
US11559257B2 (en) * | 2019-12-23 | 2023-01-24 | Covidien Lp | Catheter insert including one or more sensors |
US11617543B2 (en) | 2019-12-30 | 2023-04-04 | Sentinel Medical Technologies, Llc. | Catheter for monitoring pressure |
US11672599B2 (en) | 2020-03-09 | 2023-06-13 | Bolt Medical, Inc. | Acoustic performance monitoring system and method within intravascular lithotripsy device |
US20210290286A1 (en) | 2020-03-18 | 2021-09-23 | Bolt Medical, Inc. | Optical analyzer assembly and method for intravascular lithotripsy device |
US11707323B2 (en) | 2020-04-03 | 2023-07-25 | Bolt Medical, Inc. | Electrical analyzer assembly for intravascular lithotripsy device |
US11717642B2 (en) | 2020-04-24 | 2023-08-08 | Covidien Lp | Catheter including one or more sensors |
US11703365B2 (en) | 2020-07-14 | 2023-07-18 | C. R. Bard, Inc. | Automatic fluid flow system with push-button connection |
US11744498B2 (en) | 2020-07-17 | 2023-09-05 | Covidien Lp | Catheter system |
US11458249B2 (en) * | 2020-09-03 | 2022-10-04 | BrainSpace, Inc. | Body fluid management systems for patient care |
US11864893B2 (en) | 2020-09-04 | 2024-01-09 | Covidien Lp | Oxygen sensor calibration |
US11944737B2 (en) | 2020-11-24 | 2024-04-02 | C. R. Bard, Inc. | Air venting meter lid adapter |
US11931151B2 (en) | 2020-12-22 | 2024-03-19 | C. R. Bard, Inc. | Automated urinary output measuring system |
US11931541B2 (en) | 2021-01-08 | 2024-03-19 | C. R. Bard, Inc. | Connector for selective occlusion of drainage tube |
US11672585B2 (en) | 2021-01-12 | 2023-06-13 | Bolt Medical, Inc. | Balloon assembly for valvuloplasty catheter system |
EP4277996A1 (en) * | 2021-01-15 | 2023-11-22 | QSM Diagnostics, Inc. | Materials and methods for diagnosis |
JP2021072926A (ja) * | 2021-01-26 | 2021-05-13 | 株式会社塚田メディカル・リサーチ | 膀胱尿動態測定装置 |
US11944331B2 (en) | 2021-02-26 | 2024-04-02 | Fastwave Medical Inc. | Intravascular lithotripsy |
US11911056B2 (en) | 2021-02-26 | 2024-02-27 | Fastwave Medical Inc. | Intravascular lithotripsy |
WO2022197792A1 (en) * | 2021-03-17 | 2022-09-22 | Board Of Regents Of The University Of Nebraska | Catheter placement devices |
WO2022209703A1 (ja) * | 2021-03-31 | 2022-10-06 | テルモ株式会社 | 測定アダプタ、測定システムおよび測定方法 |
US11648057B2 (en) | 2021-05-10 | 2023-05-16 | Bolt Medical, Inc. | Optical analyzer assembly with safety shutdown system for intravascular lithotripsy device |
US11806075B2 (en) | 2021-06-07 | 2023-11-07 | Bolt Medical, Inc. | Active alignment system and method for laser optical coupling |
JPWO2023007810A1 (ja) * | 2021-07-30 | 2023-02-02 | ||
CA3237129A1 (en) * | 2021-11-03 | 2023-05-11 | Caitlin D.C. Morse | In-line measurement and/or detection of analytes, contaminants, and physical characteristics in body fluid management systems |
US11839391B2 (en) | 2021-12-14 | 2023-12-12 | Bolt Medical, Inc. | Optical emitter housing assembly for intravascular lithotripsy device |
CN114224320B (zh) * | 2021-12-31 | 2023-01-17 | 深圳融昕医疗科技有限公司 | 自适应多通道信号融合的鼾声检测方法、设备及系统 |
CN114587325B (zh) * | 2022-03-03 | 2022-12-27 | 无锡市人民医院 | 一种胰腺炎腹腔高压的无创测压装置及使用方法 |
WO2023235665A1 (en) | 2022-06-01 | 2023-12-07 | Fastwave Medical Inc. | Intravascular lithotripsy |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5892339A (ja) * | 1981-11-26 | 1983-06-01 | 日本電気三栄株式会社 | 生体内圧測定装置 |
JP3471927B2 (ja) * | 1994-11-01 | 2003-12-02 | 株式会社サンモア | カテーテル及びこれに接続する吸引装置 |
US6461332B1 (en) * | 1998-10-19 | 2002-10-08 | Surx, Inc. | Urinary incontinence diagnostic system |
ATE378080T1 (de) * | 2001-07-31 | 2007-11-15 | Scott Lab Inc | Vorrichtung zur durchführung einer iv infusion |
GB2395128B (en) * | 2002-11-14 | 2005-11-16 | Europ Technology For Business | Urinary drainage catheter |
EP1703922B2 (en) * | 2003-12-22 | 2019-12-04 | Medela Holding AG | Drainage apparatus |
WO2007005851A2 (en) * | 2005-07-05 | 2007-01-11 | C.R. Bard, Inc. | Multi-functional and modular urine collection system |
US9011328B2 (en) * | 2005-10-18 | 2015-04-21 | Pneumoflex Systems, Llc | Oral-esophageal-gastric device with esophageal cuff to reduce gastric reflux and/or emesis |
JP4857764B2 (ja) * | 2005-12-27 | 2012-01-18 | ブラザー工業株式会社 | ヘッドクリーニング装置 |
WO2008103625A2 (en) * | 2007-02-21 | 2008-08-28 | C.R. Bard, Inc. | Acs therapy system |
US8192368B2 (en) * | 2008-06-09 | 2012-06-05 | Gentera Holdings, Llc | Pressure sensing catheter |
DE102009017034B3 (de) * | 2009-04-09 | 2010-06-17 | Pulsion Medical Systems Ag | Vorrichtung zur Messung des Blasendrucks |
WO2012016179A1 (en) * | 2010-07-30 | 2012-02-02 | C.R. Bard, Inc. | Automated method of pooling elimination with a biological fluid collection system |
US9962516B2 (en) * | 2010-09-09 | 2018-05-08 | University Of Florida Research Foundation, Incorporated | Context-sensitive flow interrupter and drainage outflow optimization system |
US9655555B2 (en) * | 2011-03-07 | 2017-05-23 | Potrero Medical, Inc. | Sensing foley catheter |
WO2014043650A2 (en) * | 2012-09-17 | 2014-03-20 | Theranova, Llc | Systems, devices and methods for urine monitoring |
CN205095077U (zh) * | 2015-10-22 | 2016-03-23 | 四川医达科技有限公司 | 一种医用负压吸引器 |
-
2014
- 2014-06-27 JP JP2016524238A patent/JP6436402B6/ja active Active
- 2014-06-27 CA CA2916939A patent/CA2916939C/en active Active
- 2014-06-27 AU AU2014302183A patent/AU2014302183A1/en not_active Abandoned
- 2014-06-27 WO PCT/US2014/044565 patent/WO2014210453A2/en active Application Filing
- 2014-06-27 EP EP21171621.2A patent/EP3884859A1/en active Pending
- 2014-06-27 EP EP14817903.9A patent/EP3013222A4/en not_active Ceased
-
2015
- 2015-12-22 US US14/978,785 patent/US20160183819A1/en active Pending
-
2018
- 2018-11-01 JP JP2018206198A patent/JP6761843B2/ja active Active
-
2019
- 2019-05-23 AU AU2019203634A patent/AU2019203634B2/en active Active
-
2020
- 2020-09-07 JP JP2020149786A patent/JP7187510B2/ja active Active
-
2021
- 2021-03-03 AU AU2021201400A patent/AU2021201400A1/en not_active Abandoned
-
2022
- 2022-11-30 JP JP2022190883A patent/JP2023029920A/ja active Pending
-
2023
- 2023-02-20 AU AU2023200993A patent/AU2023200993A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2023029920A (ja) | 2023-03-07 |
JP2021000471A (ja) | 2021-01-07 |
WO2014210453A3 (en) | 2015-10-29 |
JP7187510B2 (ja) | 2022-12-12 |
JP6761843B2 (ja) | 2020-09-30 |
WO2014210453A2 (en) | 2014-12-31 |
JP6436402B2 (ja) | 2018-12-12 |
EP3013222A4 (en) | 2017-05-24 |
US20160183819A1 (en) | 2016-06-30 |
AU2019203634A1 (en) | 2019-06-13 |
JP2019063539A (ja) | 2019-04-25 |
AU2023200993A1 (en) | 2023-03-23 |
CA2916939A1 (en) | 2014-12-31 |
JP2016531650A (ja) | 2016-10-13 |
AU2014302183A1 (en) | 2016-02-11 |
CA2916939C (en) | 2023-12-12 |
EP3013222A2 (en) | 2016-05-04 |
AU2019203634B2 (en) | 2021-01-21 |
AU2021201400A1 (en) | 2021-03-25 |
EP3884859A1 (en) | 2021-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7187510B2 (ja) | 感知フォーリー・カテーテル | |
AU2020256358B2 (en) | Systems, devices and methods for sensing physiologic data and draining and analyzing bodily fluids | |
US20210093243A1 (en) | Systems, devices and methods for draining and analyzing bodily fluids and assessing health | |
WO2014043650A2 (en) | Systems, devices and methods for urine monitoring | |
WO2018136306A1 (en) | Systems, devices and methods for draining and analyzing bodily fluids | |
WO2021126698A1 (en) | Systems, devices and methods for draining and analyzing bodily fluids and assessing health | |
WO2022266584A1 (en) | Systems, devices and methods for draining and analyzing bodily fluids, pressures and assessing health |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160803 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170509 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170810 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180227 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180306 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180320 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180726 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180810 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181002 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181101 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6436402 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |